| Literature DB >> 30201549 |
Thiago Monteiro Paiva Fernandes1, Steven M Silverstein2, Pamela D Butler3, Szabolcs Kéri4, Lucas Galdino Santos5, Renata Lyra Nogueira5, Natanael Antonio Santos5.
Abstract
Schizophrenia patients (SCZ) demonstrate deficits in many domains of mental functioning, including visual perception. An issue that has been relatively unexplored, in terms of explaining variation in visual function in SCZ, however, is medication use. The present study explored potential medication effects on color vision in SCZ, a process that is strongly linked to dopaminergic function in the retina. SCZ patients who had clear-cut either typical (n = 29) or atypical (n = 29) monotherapy, without any other concurrent medication, and a group of age- and gender-matched healthy controls participated in the study. Color vision was assessed by the Cambridge Colour Test, using the Trivector and Ellipse subtests. The results demonstrated impaired color perception in patients with schizophrenia, especially in those receiving typical antipsychotics, but these deficits were subtle and not generalized to all parameters. Our findings are consistent with the known neurophysiology of the retina and visual pathways, and with the effects of dopamine blocking medications, but the results should be carefully interpreted.Entities:
Keywords: Antipsychotics; Cambridge Colour Test; Color vision; Psychiatry; Schizophrenia
Mesh:
Substances:
Year: 2018 PMID: 30201549 DOI: 10.1016/j.schres.2018.09.002
Source DB: PubMed Journal: Schizophr Res ISSN: 0920-9964 Impact factor: 4.939